ConductScience.org, home

Paper36980625

Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease.

Halperin R and 1 other. Cancers (Basel), 2023. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease. Papers, record 36980625. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980625

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.71
iCite
Revised in PubMed
2024-09-15
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Halperin RReut
2Tirosh AAmithttps://orcid.org/0000-0003-3794-9634

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06523582Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsBackground

Source ClinicalTrials.gov

Download CSV of trials

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131368132Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients.Clin Genet2019https://conductscience.org/library/papers/31368132PubMed
230714538Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.Curr Radiopharm2019https://conductscience.org/library/papers/30714538PubMed
325956795Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Lancet Oncol2015https://conductscience.org/library/papers/25956795PubMed
423392213Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.Eur J Endocrinol2013https://conductscience.org/library/papers/23392213PubMed
531392045The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.J Gastrointest Oncol2019https://conductscience.org/library/papers/31392045PubMed
627030075Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.Nat Rev Clin Oncol2016https://conductscience.org/library/papers/27030075PubMed
731737565The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients.Front Oncol2019https://conductscience.org/library/papers/31737565PubMed
828448665Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.JAMA Oncol2017https://conductscience.org/library/papers/28448665PubMed
933737209Impact of Pancreatic Neuroendocrine Tumor on Mortality in Patients With von Hippel-Lindau Disease.Endocr Pract2021https://conductscience.org/library/papers/33737209PubMed
1022415670Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with Von Hippel-Lindau syndrome (VHL).Pancreas2012https://conductscience.org/library/papers/22415670PubMed
1119704057
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
J Clin Oncol2009https://conductscience.org/library/papers/19704057PubMed
1228199314Whole-genome landscape of pancreatic neuroendocrine tumours.Nature2017https://conductscience.org/library/papers/28199314PubMed
1330849371VEGF in Signaling and Disease: Beyond Discovery and Development.Cell2019https://conductscience.org/library/papers/30849371PubMed
1427539272Survival and causes of death in patients with von Hippel-Lindau disease.J Med Genet2017https://conductscience.org/library/papers/27539272PubMed
158730290Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.J Med Genet1996https://conductscience.org/library/papers/8730290PubMed
1621386872von Hippel-Lindau disease: a clinical and scientific review.Eur J Hum Genet2011https://conductscience.org/library/papers/21386872PubMed
1721306237Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med2011https://conductscience.org/library/papers/21306237PubMed
1836358667Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review.Cancers (Basel)2022https://conductscience.org/library/papers/36358667PubMed
1933616314Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.N Engl J Med2021https://conductscience.org/library/papers/33616314PubMed
2035709961von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.Eur J Med Genet2022https://conductscience.org/library/papers/35709961PubMed

See all 62 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
39933087A New Era of Management of Von Hippel-Lindau Disease-Associated Tumors With Belzutifan.Clin J Oncol Nurs2025https://conductscience.org/library/papers/39933087PubMed
39757325New Developments in VHL-Associated Neuroendocrine Neoplasms.Curr Oncol Rep2025https://conductscience.org/library/papers/39757325PubMed
38893191Hereditary Syndromes Associated with Pancreatic and Lung Neuroendocrine Tumors.Cancers (Basel)2024https://conductscience.org/library/papers/38893191PubMed
38616993Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review.Diabetes Metab Syndr Obes2024https://conductscience.org/library/papers/38616993PubMed
38180510[Multiple neuroendocrine tumors of the pancreas].Pathologie (Heidelb)2024https://conductscience.org/library/papers/38180510PubMed

Download CSV of cited by

Genes15

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36980625

GET https://conductscience.org/api/papers/v1/36980625/references?page=2